Kornimate/medical-research-clean huggingface dataset:
dry needling vs. stretching for non-specific low back pain

Conditions: Non Specific Low Back Pain

Summary: chronic low back pain (clbp) is one of the common health issues and a leading cause of reduced mobility. it is characterized by pain during functional activities and is often associated with hamstring tightness. clbp affects individuals across all age groups. various methods are used to address low back pain, including manual therapy. manual therapy techniques include maitland mobilizations, kaltenborn mobilizations, mulligan techniques, stretching, and others. several stretching techniques have been proposed, including static stretching, dynamic stretching, ballistic stretching, and proprioceptive neuromuscular facilitation (pnf). among these, static and dynamic stretching are the most commonly used methods. static stretching is considered one of the safest and easiest techniques, which can be performed passively or actively. literature supports that stretching improves muscle flexibility, provides relaxation, reduces pain, and increases the range of motion (rom). dry needling is another physical intervention technique that has been utilized for patients with musculoskeletal disorders. current literature supports the use of dry needling for trigger points in hamstring muscles, which is a contributing factor to low back pain. the objective of this study is to compare the effects of dry needling and stretching combined with sustained natural apophyseal glides (snags) on pain, rom, muscle length, and disability in patients with non-specific low back pain. a randomized clinical trial will be conducted at hijaz hospital using convenience sampling to recruit participants. patients will be allocated into two groups (group a and group b) through simple random sampling using sealed opaque envelopes. after conventional treatment, group a will receive snags and stretching, while group b will receive snags and dry needling. outcome measures will include the goniometer for rom, the modified oswestry disability index (modi) for disability, the numeric pain rating scale (nprs) for pain, and the finger-to-floor distance test for hamstring flexibility. these measures will be assessed at baseline, at the 2nd week, and after 4 weeks. data will be analyzed using spss software (version 21). the normality of the data will be assessed using the shapiro-wilk test. based on the results, parametric or non-parametric tests will be used for within-group and between-group comparisons. snags and dry needling will be evaluated for their effectiveness in treating non-specific low back pain.


Eligibility criteria:
inclusion criteria: * minimum 3 months chronicity of low back pain * with tight hamstrings and positive passive knee extension test (12) exclusion criteria: * chronic systemic bony and soft tissue diseases * recent history of trauma * degenerative joint diseases * psychiatrist diseases

Keywords: non-specific low back pain dry needling snags rom disability muscle length
sebum collection and skin barrier function analysis

Conditions: Smoking; Acne; Atopic Dermatitis; Aging

Summary: the goal is this study is to evaluate how the skin surface lipid composition is correlated with overall sebum production, barrier function, and inflammatory disease status. we hypothesize that there will be differences in the skin surface composition among subjects of various groups: 1. young vs older healthy population 2. atopic dermatitis vs acne vs healthy controls 3. active smokers vs non-smoker controls

this study will be conducted through the use of painless tapes to collect lipid. these will be applied to the skin and removed. secondly, the barrier function will be evaluated through the use of non-invasive painless devices that measure sebum, skin water loss, and skin hydration.

Eligibility criteria:
inclusion criteria: * subjects that are 12 years of age or older exclusion criteria: * none

Keywords: younger age older age atopic dermatitis acne smoker
evaluation of a hires™ optima sound processing strategy for the hiresolution™ bionic ear

Conditions: Severe to Profound Hearing Loss; in Adult Users of Advanced Bionics HiResolution™ Bionic Ear System

Summary: the purpose of this study is to compare a new sound processing strategy to the current sound processing strategy.


Eligibility criteria:
inclusion criteria: * unilateral or bilateral user of cii/hires90k™ implant(s) (minimum of one year in each implanted ear), harmony™ bte processor(s) with hires fidelity 120™ (with or without clearvoice™) as preferred sound processing strategy * 18 years of age or older at time of implant * postlingual onset of severe-to-profound hearing loss (≥ 6 years of age) * at least moderate open-set speech recognition abilities (defined as cnc word score ≥ 50% in medical records or assessed at the baseline visit with implant alone for unilateral users, with both implants together for bilateral users) * english language proficiency * willingness to use a harmony™ bte processor and refrain from clearvoice™ use for the duration of the study * willingness and ability to participate in all scheduled procedures outlined in the protocol exclusion criteria: • presence of any additional disabilities that would prevent or interfere with participation in the required speech perception testing

Keywords: cochlear implant adults hiresolution™ fidelity 120™ listening benefits noise cochlear implant benefit
efficacy of dexmedetomidine as an adjuvant to quadratus lumborum block

Conditions: Pain, Postoperative

Summary: this prospective double blinded study will be conducted over 60 pediatric patients asa (american association of anesthesiologists) i and ii between the age of 1-7 years old, who will be scheduled for unilateral groin surgery. patients will be randomly allocated into 3 study groups: control group that only received local anesthetics ( bupivacaine) group ii bupivacaine with the dexmetedomidine ( 0,5mcg/kg ) and group iii bupivacaine with the dexmedetomidine (1mcg/kg).patients in all groups will receive quadratus lumborum block. bradycardia, hypotension, atropine, and bolus fluid infusion requirements will be recorded. when there was up to a 30% decrease in basal mean blood pressure, a crystalloid infusion bolus will be given at 10 ml/kg. when bradycardia occurred , atropine will be given at a dose of 0.02 mg/kg. patients will be followed up in the postoperative recovery unit for the first 2 hours, and then in the ward. the ramsey sedation scale and watcha agitation scale were evaluated at 5, 15, 30, and 60 minutes in the postoperative recovery unit. nausea, vomiting, and other side effects were recorded if present. time to first analgesic requirement ( primary outcome) , flacc scale scores will be recorded within 24h postoperatively, total dose of analgesic consumption, incidence of postoperative complications as hypotension, bradycardia, vomiting, pruritis and respiratory depression will be recorded.


Eligibility criteria:
inclusion criteria: the study included children aged 1-7 years with asa (american society of anesthesiologists) i-ii, who underwent elective, unilateral, groin surgery (inguinal hernia, orchiopexy, hydrocele) with the consent of their families exclusion criteria: * children who were aged outside the range of 1-7 years, with asa iii or higher, allergic to local anesthetics, had an infection in the injection area, had contraindications for regional anesthesia such as coagulopathy, whose families did not give consent, were undergoing laparoscopic orchidopexy, undergoing bilateral surgery, had a body mass index of \>30 kg/m2, and were expected to be admitted to the intensive care unit during the postoperative period were excluded from the study

Keywords: dexmedetomidine bupivacaine quadratus lumborum block postoperative pain regional anesthesia pediatric anesthesia
immediate postpartum glucose tolerance testing

Conditions: Gestational Diabetes

Summary: the objective of this study is to compare the accuracy of a 2hr glucose tolerance test administered during the postpartum hospitalization with the standard of care glucose tolerance testing (administered at 6 weeks postpartum). the primary hypothesis is that the glucose tolerance test administered in the postpartum period will be accurate and will improve compliance with postpartum testing for gestational diabetics.

gestational diabetes affects approximately 5-10% of pregnancies and its prevalence continues to increase as rates of obesity and metabolic disease increase in reproductive age women. women diagnosed with gestational diabetes carry an increased risk of developing type 2 diabetes later in life, even if their glucose tolerance initially normalizes following delivery. the gold standard assessment of glucose tolerance postpartum is a two hour glucose tolerance test (gtt) that is completed between six and twelve weeks' postpartum. unfortunately, the compliance rate with this test is low, ranging from 30 - 50% by most reports. as a result, a large number of women with glucose intolerance are missed due to noncompliance with postpartum testing, thereby forfeiting the opportunity for diagnosis, treatment and prevention of longterm health consequences. the postpartum hospital stay provides a unique opportunity to increase compliance with glucose tolerance testing due to an increased rate of patient capture. however, it is unknown if administration of a glucose tolerance test in the immediate postpartum period would adequately identify women with persistent glucose intolerance. the current study aims to provide data towards the accuracy of an immediate postpartum gtt in a population of women with gestational diabetes and provide follow-up data on women with abnormal testing.

Eligibility criteria:
inclusion criteria: * pregnant or recently postpartum (postpartum day 0 or 1) * ≥ 18 years of age * gestational age ≥34 weeks * a1 or a2 gestational diabetes exclusion criteria: * medical exclusion from completing glucose tolerance testing * steroid administration within 10 days prior to enrollment * chronic steroid use
a study of msi-1256f (squalamine lactate) to treat "wet" age-related macular degeneration

Conditions: Macular Degeneration

Summary: age-related macular degeneration (amd) is a degenerative eye disease of the retina that causes a progressive loss of central vision. amd is the leading cause of legal blindness among adults age 50 or older in the western world. amd presents in two different types - "dry" and the more severe "wet" form. wet amd is caused by the growth of abnormal blood vessels in the macula. squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. this study will test the safety and efficacy of squalamine in the treatment of amd.


Eligibility criteria:
inclusion criteria: * adult subjects ≥ 50 years of age. * minimally classic or active occult choroidal neovascularization associated with age-related macular degeneration in one or both eyes. * baseline best corrected visual acuity score between 35 to 65 letters according to the early treatment of diabetic retinopathy study protocol. * central retinal thickness by optical coherence tomography of \> 250 microns. * lesions \> 9 disc areas. * \> 25% fibrosis in the lesion. exclusion criteria: * previous history of triamcinolone, bevacizumab, ranibizumab, or pegaptanib sodium injection therapy in the study eye. * retinal or optic nerve disease. * uncontrolled diabetes. * ongoing malignancy.
impact of asthma treatments on daily activities

Conditions: Asthma; Allergies

Summary: the primary objective of this web-based, cross-sectional study is to assess and compare the ability to sleep, work or go to school, and to participate in leisure activities among subjects who are receiving xolair treatment and subjects who were eligible to receive xolair, but instead have been using advair for at least 1 year.


Eligibility criteria:
inclusion criteria: * have asthma and allergies * currently taking xolair® or advair® * started xolair® treatment within the last 4 to 12 months or have been taking advair® for at least 12 months * between 18 and 55 years of age * a non-smoker for at least 6 months * have internet access

Keywords: asthma allergies xolair advair
decolonization to reduce after-surgery events of surgical site infection

Conditions: Surgical Site Infection

Summary: the decrease ssi trial (decolonization to reduce after-surgery events of surgical site infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. this trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce ssi.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * recent open (not solely laparoscopic) surgery involving an abdominal incision within the past 14 days. for cesarean section, recruitment restricted to bmi ≥ 40. * able to communicate regularly by phone * able to bathe, shower or have this task performed by a caregiver exclusion criteria: * transfer to an acute care hospital * discharged to receive end-of-life hospice measures * discharged more than 14 days after surgery * allergic to mupirocin and/or chlorhexidine * active infection at enrollment\* \*refers to 1. infections requiring systemic antibacterial agents, so viral illness (e.g., covid, flu) is not an exclusion. 2. topical antibacterial agents do not count toward exclusion (e.g., topical products for acne) 3. prophylactic antibacterial agents do not count toward exclusion * surgical incision not closed at discharge

Keywords: surgical site infection ssi
a trial for evaluating both safety and preliminary efficacy of a single infusion of stimulated autologous cd4+t cells in patients with relapsing- remitting multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous cd4+ t cells in patients with relapsing-remitting multiple sclerosis. the study duration for the patients (from start of baseline to end of follow-up) is 270 days.


Eligibility criteria:
inclusion criteria: * males and females 18 to 60 years of age * patients closely followed up for at least one year prior to inclusion (i.e. prior to the start of the baseline phase) if the diagnosis of the disease was made more than one year ago, to ensure that all possible episodes of clinical relapses which occurred during this interval of time were recorded and documented * multiple sclerosis that meets the 2010 revised mcdonald criteria * relapsing/remitting type of multiple sclerosis (which includes clinically isolated syndromes if imaging shows brain lesions disseminated in space and time) * radiologically active disease defined by at least one gadolinium-enhancing lesion on a t1-weighted magnetic resonance imaging brain scan performed recently (i.e. within 3 months prior to inclusion) * disease-modifying drug naïve patients or patients with stable and adequately taken disease-modifying therapy (interferon β-1, glatiramer acetate, or dimethyl fumarate) for at least six months before inclusion (note: other disease modifying drugs might be added at a later date, depending on the results of current investigations) * edss score \<= 5.5 * positive predictive test in vitro for patient's cd4+ cell reactivity to immunogenic peptide * women of childbearing age must have a negative pregnancy test and must use adequate contraception during the treatment and follow-up phase of the study (three pregnancy tests will be required prior to and during the study: (1) during the screening phase, (2) about one week prior to leukapheresis, and (3) about one week prior to re-infusion of autologous cells) * fully informed written consent obtained exclusion criteria: * positive only for the hla drb1\*0101, drb1\*0102, drb1\*0401, drb1\*0426 alleles or for the combination of the previous alleles. * evidence of clinical relapse and use of intravenous or oral corticosteroids within 30 days prior to inclusion * therapeutic escalation anticipated (including change of disease modifying drug), other than the cell-based immunotherapy of this study, within the next six months * significant coexisting systemic disease including renal insufficiency * positive serology for hepatitis b and c, aids and syphilis * participation in another interventional clinical study, currently or during the past three months
the effect of a musical toy (xylophone) on pain, fear, and parental satisfaction during peripheral intravenous cannulation in children aged 3 to 6 years

Conditions: Pain Management

Summary: this randomized controlled trial investigates the effects of using a musical toy (xylophone) as a distraction technique during peripheral intravenous cannulation on pain, fear, and parental satisfaction in hospitalized children aged 3 to 6 years. the study will be conducted in the pediatric health and diseases clinic of trakya university in edirne, turkey. a total of 64 children will be randomly assigned to either the intervention group or the control group. children in the intervention group will be encouraged to play with a xylophone, accompanied by a nurse, before and during the cannulation procedure. the control group will receive standard care without any distraction. pain levels will be measured using the wong-baker faces pain rating scale, fear will be assessed using the children's fear scale, and parental satisfaction will be evaluated using the pedsql healthcare satisfaction scale. the primary objective is to evaluate whether the use of a musical toy during iv insertion reduces pain and fear in children. the secondary objective is to determine whether parental satisfaction with the healthcare experience is improved in the intervention group. data will be collected before, during, and after the procedure. this study is expected to contribute to the evidence base supporting the use of non-pharmacological methods in pediatric pain management and to promote child-friendly approaches in clinical settings.


Eligibility criteria:
inclusion criteria: * children aged between 3 and 6 years * hospitalized and scheduled for peripheral intravenous cannulation * no hearing or mental disabilities * no chronic disease associated with pain * no analgesic use in the past 6 hours * one parent present during the procedure * both child and parent voluntarily agree to participate * intravenous cannulation to be performed in a single attempt * parent/guardian is literate exclusion criteria: * children with hearing impairment or mental disabilities * use of analgesics within the last 6 hours * presence of chronic pain conditions * parental refusal to participate * failed intravenous cannulation attempt * illiterate parent/guardian * any parental mental disability * child or parent unwilling to participate
predicting sleep, smoking, and lung health disparities in african american adults

Conditions: Sleep; Lung Diseases; Smoking

Summary: this 5-year prospective, observational study will: (1) determine the individual, social, and environmental predictors of sleep duration, quality, latency, efficiency, timing and regularity in african american smokers, (2) quantify the prospective relationship between multiple metrics of sleep with tobacco use, such that a sleep phenotype of risk for smoking is defined, and (3) examine the extent to which short sleep (\<7 hrs) and other unhealthy sleep metrics, predicts lung function through smoking behaviors and inflammation, in 480 african americans at risk for advancing copd (gold stage 0-2 and current smoker). study subjects will be recruited via temple health system sites. following eligibility screening, initially eligible subjects will provide written study consent and complete an in-home sleep assessment to rule out the exclusionary moderate-severe sleep apnea and other sleep disorders. consenting and eligible subjects will be entered into the study and across the 60-month data collection period, complete 8 assessments: 4 annual clinical based assessments, interspersed by 4 mid-year, phone-based, self-report assessments.


Eligibility criteria:
inclusion criteria: 1. self-reported african american, white, or mixed ethnicity. 2. 40 - 67 years. 3. gold stage 0-3 as assessed by spirometry. 4. no moderate-severe sleep disorders or use of sleep medication. 5. self-reported current cigarette smoker as defined by smoking one or more cigarettes in the last month. 6. able to communicate in english and provide written informed consent. exclusion criteria: 1. self-reported ethnicity (in full or part) other than black/african american or white. 2. \< 40 years of age. 3. not a current cigarette smoker (\< 1 cigarette in last month). 4. gold stage \>3. 5. presents with a diagnosed moderate-severe sleep disorder 6. use of any sleep medication. -
clinical characteristic of recurrent acute rhinosinusitis in children

Conditions: Acute Recurrent Sinusitis

Summary: the purpose of this study is to determine the clinical characteristic of recurrent acute rhinosinusitis in children.


Eligibility criteria:
inclusion criteria: * children the age less than 15 years with recurrent acute rhinosinusitis who are attending the pediatric allergy clinic during jan 2010 - dec 2012. exclusion criteria: * children who had lost medical record.

Keywords: characteristic recurrent acute rhinosinusitis children
intraoperative hyperoxia and mins

Conditions: Hyperoxia; Myocardial Infarction; Myocardial Injury

Summary: oxygen therapy is administered to all patients during general anesthesia to maintain tissue oxygenation and prevent hypoxia and ischemia. however, liberal use of oxygen may lead to hyperoxia and some studies suggest that supranormal levels of arterial oxygen saturation may lead to complications. in this post hoc substudy of the vision cohort, we plan to assess the association between perioperative inspired oxygen fraction (fio2) and myocardial injury after non-cardiac surgery (mins).

patients will be divided into five groups of median intraoperative fio2 (quintiles), in which baseline characteristics and outcomes will be illustrated. the odds ratio (or) for the primary and secondary outcomes will be calculated in a logistic regression analysis with median fio2 (continuous variable) as independent variable. analyses are performed with multiple logistic regression with adjustment for the following potentially confounding variables: age ≥75 years. male sex. current atrial fibrillation. history of diabetes. history of congestive heart failure. history of coronary artery disease. history of recent (i.e., \< 6 months) high-risk coronary artery disease. history of stroke. history of peripheral vascular disease. history of hypertension. preoperative egfr (\<30 vs. 30-44 vs. 45-59 vs. ≥60 ml/min/1.73m2). low-risk surgery. duration of surgery.

Eligibility criteria:
inclusion criteria: * patients entered in the vision database, aged 18 years or above, undergoing noncardiac surgery in general anesthesia. exclusion criteria: * patients with unobtainable data on perioperative fio2. * patients with unobtainable data on postoperative troponin.